Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Jul 5;27(Suppl 3):16–21. doi: 10.1002/clc.4960271506

Cholesterol metabolism and therapeutic targets: Rationale for targeting multiple metabolic pathways

Stephen D Turley 1,✉
PMCID: PMC6654229  PMID: 15239487

Abstract

The liver is the major regulator of the plasma low density lipoprotein cholesterol (LDL‐C) concentration because it is not only the site of formation of very low density lipoproteins (VLDL), the precursors of most LDL in the circulation, but it is also the organ where the bulk of receptor‐mediated clearance of LDL takes place. The liver also initially clears all the cholesterol that is absorbed from the small intestine. The absorption of excess cholesterol can potentially increase the amount of cholesterol stored in the liver. This, in turn, can result in increased VLDL secretion, and hence LDL formation, and also downregulation of hepatic LDL receptor activity. Such events will potentially increase plasma LDL‐C levels. The converse situation occurs when cholesterol absorption is inhibited. Cholesterol enters the lumen of the small intestine principally from bile and diet. The major steps involved in the absorption process have been characterized. On average, about half of all cholesterol entering the intestine is absorbed, but the fractional absorption rate varies greatly among individuals. While the basis for this variability is not understood, it may partly explain why some patients respond poorly or not at all to statins and other classes of lipid‐lowering drugs. There are few data relating to racial differences in cholesterol absorption. One study reported a significantly higher rate in African Americans compared with non‐African Americans. Multiple lipid‐lowering drugs that target pathways involving the absorption, synthesis, transport, storage, catabolism, and excretion of cholesterol are available. Ezetimibe selectively blocks cholesterol absorption and lowers plasma LDL‐C levels by an average of 18%. When ezetimibe is coadministered with lower doses of statins, there is an additive reduction in LDL‐C level, which equals the reduction achieved with maximal doses of statins alone. Dual inhibition of cholesterol synthesis and absorption is an effective new strategy for treating hypercholesterolemia.

Full Text

The Full Text of this article is available as a PDF (60.6 KB).

References

  • 1. Cook RP: Distribution of sterols in organisms and in tissues In Cholesterol. Chemistry, Biochemistry, and Pathology (Ed. Cook RP.), p. 145–180. New York: Academic Press Inc., 1958. [Google Scholar]
  • 2. Vanhanen H, Kesaniemi YA, Miettinen TA: Pravastatin lowers serum cholesterol, cholesterol‐precursor sterols, fecal steroids, and cholesterol absorption in man. Metabolism 1992; 41: 588–595 [DOI] [PubMed] [Google Scholar]
  • 3. Sudhop T, Lütjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943–1948 [DOI] [PubMed] [Google Scholar]
  • 4. Turley SD, Dietschy JM: The metabolism and excretion of cholesterol by the liver In The Liver: Biology and Pathobiology (Eds. Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA.), p. 617–641. New York: Raven Press, 1988. [Google Scholar]
  • 5. Dietschy JM, Turley SD, Spady DK: Role of liver in the maintenance of cholesterol and low‐density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637–1659 [PubMed] [Google Scholar]
  • 6. Grundy SM: Alternative approaches to cholesterol‐lowering therapy. Am J Cardiol 2002; 90: 1135–1138 [DOI] [PubMed] [Google Scholar]
  • 7. Tso P: Intestinal lipid absorption In Physiology of the Gastrointestinal Tract (Ed. Johnson LR.), p. 1867–1907. New York: Raven Press, 1994. [Google Scholar]
  • 8. Phillips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH: Improved metabolic control reduces the number of postprandial apolipoprotein B‐48‐containing particles in Type 2 diabetes. Atherosclerosis 2000; 148: 283–291 [DOI] [PubMed] [Google Scholar]
  • 9. Grundy SM: Absorption and metabolism of dietary cholesterol. Ann Rev Nutr 1983; 3: 71–96 [DOI] [PubMed] [Google Scholar]
  • 10. Ginsberg HN: New perspectives on atherogenesis: Role of abnormal triglyceride‐rich lipoprotein metabolism. Circulation 2002; 106: 2137–2142 [DOI] [PubMed] [Google Scholar]
  • 11. Mamo JCL, Proctor SD, Smith D: Retention of chylomicron remnants by arterial tissue: Importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998; 141: S63–S69 [DOI] [PubMed] [Google Scholar]
  • 12. Turley SD, Dietschy JM: Sterol absorption by the small intestine. Curr Opin Lipidol 2003; 14: 233–240 [DOI] [PubMed] [Google Scholar]
  • 13. Altmann SW, Davis HR Jr, Zhu L‐J, Yao X, Hoos LM, Tetzloff G, Iyer SPN, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann‐Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201–1204 [DOI] [PubMed] [Google Scholar]
  • 14. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290: 1771–1775 [DOI] [PubMed] [Google Scholar]
  • 15. Lee M‐H, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK, Salen G, Dean M, Patel SB: Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001; 27: 79–83 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Connor WE, Lin DS: The intestinal absorption of dietary cholesterol by hypercholesterolemic (type II) and normocholesterolemic humans. J Clin Invest 1974; 53: 1062–1070 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Nestel PJ, Havenstein N, Homma Y, Scott TW, Cook LJ: Increased sterol excretion with polyunsaturated‐fat high‐cholesterol diets. Metabolism 1975; 24: 189–198 [DOI] [PubMed] [Google Scholar]
  • 18. Crouse JR, Grundy SM, Johnson JH: Effects of AOMA on cholesterol metabolism in man. Metabolism 1982; 31: 733–739 [DOI] [PubMed] [Google Scholar]
  • 19. McMurry MP, Connor WE, Lin DS, Cerqueira MT, Connor SL: The absorption of cholesterol and the sterol balance in the Tarahumara Indians of Mexico fed cholesterol‐free and high cholesterol diets. Am J Clin Nutr 1985; 41: 1289–1298 [DOI] [PubMed] [Google Scholar]
  • 20. Briones ER, Steiger DL, Palumbo PJ, O'Fallon WM, Langworthy AL, Zimmerman BR, Kottke BA: Sterol excretion and cholesterol absorption in diabetics and nondiabetics with and without hyperlipidemia. Am J Clin Nutr 1986; 44: 353–361 [DOI] [PubMed] [Google Scholar]
  • 21. Kesäniemi YA, Miettinen TA: Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 1987; 17: 391–395 [DOI] [PubMed] [Google Scholar]
  • 22. McNamara DJ, Kolb R, Parker TS, Batwin H, Samuel P, Brown CD, Ahrens EH Jr: Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity. J Clin Invest 1987; 79: 1729–1739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Kern F Jr: Normal plasma cholesterol in an 88‐year‐old man who eats 25 eggs a day. N Engl J Med 1991; 324: 896–899 [DOI] [PubMed] [Google Scholar]
  • 24. Sehayek E, Nath C, Heinemann T, McGee M, Seidman CE, Samuel P, Breslow JL: Ushape relationship between change in dietary cholesterol absorption and plasma lipoprotein responsiveness and evidence for extreme interindividual variation in dietary cholesterol absorption in humans. J Lipid Res 1998; 39: 2415–2422 [PubMed] [Google Scholar]
  • 25. Bosner MS, Lange LG, Stenson WF, Ostlund RE Jr: Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res 1999; 40: 302–308 [PubMed] [Google Scholar]
  • 26. Mittendorfer B, Ostlund RE Jr, Patterson BW, Klein S: Orlistat inhibits dietary cholesterol absorption. Obes Res 2001; 9: 599–604 [DOI] [PubMed] [Google Scholar]
  • 27. Rajaratnam RA, Gylling H, Miettinen TA: Cholesterol absorption, synthesis, and fecal output in postmenopausal women with and without coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 1650–1655 [DOI] [PubMed] [Google Scholar]
  • 28. Beynen AC, Katan MB, Van Zutphen LFM: Hypo‐ and hyperresponders: Individual differences in the response of serum cholesterol concentration to changes in diet In Advances in Lipid Research (Eds. Paoletti R, Kritchevsky D.), p. 115–171. New York: Academic Press, Inc., 1987. [DOI] [PubMed] [Google Scholar]
  • 29. Schwarz M, Davis DL, Vick BR, Russell DW: Genetic analysis of intestinal cholesterol absorption in inbred mice. J Lipid Res 2001; 42:1801‐1811 [PubMed] [Google Scholar]
  • 30. Sehayek E: Genetic regulation of cholesterol absorption and plasma plant sterol levels: Commonalities and differences. J Lipid Res 2003; 44: 2030–2038 [DOI] [PubMed] [Google Scholar]
  • 31. Miettinen TA, Gylling H, Strandberg T, Sarna S: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian Simvastatin Survival Study. Finnish 4S Investigators. Br Med J 1998; 316: 1127–1130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Grundy SM, Ahrens EH, Salen G: Interruption of the enterohepatic circulation of bile acids in man: Comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78: 94–121 [PubMed] [Google Scholar]
  • 33. Davidson MH, Dillon MA, Gordon B, Jones PJ, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK: Colesevelam hydrocholoride (Cholestagel). A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 1893–1900 [DOI] [PubMed] [Google Scholar]
  • 34. Black DM: Gut‐acting drugs for lowering cholesterol. Curr Atheroscler Reports 2002; 4: 71–75 [DOI] [PubMed] [Google Scholar]
  • 35. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003; 78: 965–978 [DOI] [PubMed] [Google Scholar]
  • 36. Crouse JR, Grundy SM: Effects of sucrose polyester on cholesterol metabolism in man. Metabolism 1979; 28: 994–1000 [DOI] [PubMed] [Google Scholar]
  • 37. Kesäniemi YA, Grundy SM: Turnover of low density lipoproteins during inhibition of cholesterol absorption by neomycin. Arteriosclerosis 1984; 4: 41–48 [DOI] [PubMed] [Google Scholar]
  • 38. Knopp RH, Dujovne CA, LeBeaut A, Lipka LJ, Suresh R, Veltri EP: Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003; 57: 363–368 [PubMed] [Google Scholar]
  • 39. Gagné C, Gaudet D, Bruckert E: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469–2475 [DOI] [PubMed] [Google Scholar]
  • 40. Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084–1091 [DOI] [PubMed] [Google Scholar]
  • 41. Salen G, von Bergmann K, Lütjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B: Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004; 109: 966–971 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Bruckert E: New advances in lipid‐modifying therapies for reducing cardiovascular risk. Cardiology 2002; 97: 59–66 [DOI] [PubMed] [Google Scholar]
  • 43. Sudhop T, von Bergmann K: Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 2002; 62: 2333–2347 [DOI] [PubMed] [Google Scholar]
  • 44. Ginsberg HN: Treatment for patients with the metabolic syndrome. Am J Cardiol 2003; 91: 29E‐39E [DOI] [PubMed] [Google Scholar]
  • 45. Turley SD, Spady DK, Dietschy JM: Identification of a metabolic difference accounting for the hyper‐ and hyporesponder phenotypes of cynomolgus monkey. J Lipid Res 1997; 38: 1598–1611 [PubMed] [Google Scholar]
  • 46. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125–2134 [DOI] [PubMed] [Google Scholar]
  • 47. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, Sun S, LeBeaut AP, Sager PT, Veltri EP: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double‐blind trial. Circulation 2003; 107: 2409–2415 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES